David Oldach

David Oldach

Auto-generated profile, based on publicly available information

David Oldach

Department of Medicine and Institute of Human Virology; University of Maryland School of Medicine; Baltimore MD 21201

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CLC. Logvinoff
C. Logvinoff
MMM. E. Major
M. E. Major
DOD. Oldach
D. Oldach
SHS. Heyward
S. Heyward
ATA. Talal
A. Talal
JMJane Mckeating
Jane Mckeating
Little is known about the role of Abs in determining the outcome of hepatitis C virus (HCV) infection. By using infectious retroviral pseudotypes bearing HCV glycoproteins, we measured neutralizing Ab (nAb) responses during acute and chronic HCV infection. In seven acutely infected health care workers, only two developed a nAb response that failed to associate with viral clearance. In contrast, the majority of chronically infected patients had nAbs. To determine the kinetics of strain-specific and crossreactive nAb emergence, we studied patient H, the source of the prototype genotype 1a H77 HCV strain. An early weak nAb response, specific for the autologous virus, was detected at seroconversion. However, neutralization of heterologous viruses was detected only between 33 and 111 weeks of infection. We also examined the development of nAbs in 10 chimpanzees infected with H77 clonal virus. No nAb responses were detected in three animals that cleared virus, whereas strain-specific nAbs were detected in six of the seven chronically infected animals after ≈50 weeks of infection. The delayed appearance of high titer crossreactive nAbs in chronically infected patients suggests that selective mechanism(s) may operate to prevent the appearance of these Abs during acute infection. The long-term persistence of these nAbs in chronically infected patients may regulate viral replication.

1 November 2000 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
PDF file
HBHolly A. Bowers
Holly A. Bowers
TTTorstein Tengs
Torstein Tengs
HGHoward B. Glasgow
Howard B. Glasgow
JBJoAnn M. Burkholder
JoAnn M. Burkholder
PRParke A. Rublee
Parke A. Rublee
DODavid W. Oldach
David W. Oldach
Pfiesteria complex species are heterotrophic and mixotrophic dinoflagellates that have been recognized as harmful algal bloom species associated with adverse fish and human health effects along the East Coast of North America, particularly in its largest (Chesapeake Bay in Maryland) and second largest (Albermarle-Pamlico Sound in North Carolina) estuaries. In response to impacts on human health and the economy, monitoring programs to detect the organism have been implemented in affected areas. However, until recently, specific identification of the two toxic species known thus far, Pfiesteria piscicida and P. shumwayae (sp. nov.), required scanning electron microscopy (SEM). SEM is a labor-intensive process in which a small number of cells can be analyzed, posing limitations when the method is applied to environmental estuarine water samples. To overcome these problems, we developed a real-time PCR-based assay that permits rapid and specific identification of these organisms in culture and heterogeneous environmental water samples. Various factors likely to be encountered when assessing environmental samples were addressed, and assay specificity was validated through screening of a comprehensive panel of cultures, including the two recognized Pfiesteria species, morphologically similar species, and a wide range of other estuarine dinoflagellates. Assay sensitivity and sample stability were established for both unpreserved and fixative (acidic Lugol's solution)-preserved samples. The effects of background DNA on organism detection and enumeration were also explored, and based on these results, we conclude that the assay may be utilized to derive quantitative data. This real-time PCR-based method will be useful for many other applications, including adaptation for field-based technology.

1 October 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TBTHOMAS BERG
THOMAS BERG
PMPatrick Marcellin
Patrick Marcellin
Fabien ZoulimFabien Zoulim
Fabien Zoulim
BMBernd Moller
Bernd Moller
HTHuy Trinh
Huy Trinh
FRFranck Rousseau
Franck Rousseau

17 October 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
SZStefan Zeuzem
Stefan Zeuzem
PBPeter Buggisch
Peter Buggisch
KAKosh Agarwal
Kosh Agarwal
PMPatrick Marcellin
Patrick Marcellin
DSDaniel Sereni
Daniel Sereni
GFGraham R. Foster
Graham R. Foster
Tegobuvir (GS-9190), a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor, and GS-9256, an NS3 serine protease inhibitor, individually have activity against hepatitis C virus (HCV) genotype 1. The antiviral activity of tegobuvir and GS-9256 as oral combination therapy, or together with ribavirin (RBV) or pegylated interferon (Peg-IFN) alpha-2a and RBV, was assessed in a phase II, randomized, open-label trial. Treatment-naïve patients with genotype 1 HCV were assigned 28 days of tegobuvir 40 mg twice-daily (BID) and GS-9256 75 mg BID (n = 16), tegobuvir and GS-9256 plus RBV 1,000-1,200 mg daily (n = 15), or tegobuvir and GS-9256 plus Peg-IFN alpha-2a (180 μg once-weekly)/RBV (n = 15). The primary efficacy endpoint was rapid virologic response (RVR), with HCV RNA <25 IU/mL at day 28. After 28 days, all patients received Peg-IFN/RBV. All patients with viral rebound or nonresponse, defined as >0.5-log10 increase in HCV RNA from nadir or <2-log decrease at day 5, initiated Peg-IFN/RBV immediately. Median maximal reductions in HCV RNA were −4.1 log10 IU/mL for tegobuvir/GS-9256, −5.1 log10 IU/mL for tegobuvir/GS-9256/RBV, and −5.7 log10 IU/mL for tegobuvir/9256/Peg-IFN/RBV. RVR was observed in 7% (1 of 15) of patients receiving tegobuvir/GS-9256, 38% (5 of 13) receiving tegobuvir/GS-9256/RBV, and 100% (14 of 14) receiving tegobuvir/9256/PEG-IFN/RBV. The addition of Peg-IFN/RBV at day 28 or earlier resulted in HCV RNA <25 IU/mL at week 24 in 67% (10 of 15), 100% (13 of 13), and 94% (13 of 14) of patients in the three treatment groups. Transient elevations in serum bilirubin occurred in all treatment groups. Conclusion: In genotype 1 HCV, adding RBV or RBV with Peg-IFN provides additive antiviral activity to combination therapy with tegobuvir and GS-9256.

11 April 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DODavid W. Oldach
David W. Oldach
CDCharles Delwiche
Charles Delwiche
KJKjetill S. Jakobsen
Kjetill S. Jakobsen
TTTorstein Tengs
Torstein Tengs
EBErnest G. Brown
Ernest G. Brown
PRParke A. Rublee
Parke A. Rublee
The newly described heterotrophic estuarine dinoflagellate Pfiesteria piscicida has been linked with fish kills in field and laboratory settings, and with a novel clinical syndrome of impaired cognition and memory disturbance among humans after presumptive toxin exposure. As a result, there is a pressing need to better characterize the organism and these associations. Advances in Pfiesteria research have been hampered, however, by the absence of genomic sequence data. We employed a sequencing strategy directed by heteroduplex mobility assay to detect Pfiesteria piscicida 18S rDNA “signature” sequences in complex pools of DNA and used those data as the basis for determination of the complete P. piscicida 18S rDNA sequence. Specific PCR assays for P. piscicida and other estuarine heterotrophic dinoflagellates were developed, permitting their detection in algal cultures and in estuarine water samples collected during fish kill and fish lesion events. These tools should enhance efforts to characterize these organisms and their ecological relationships. Heteroduplex mobility assay-directed sequence discovery is broadly applicable, and may be adapted for the detection of genomic sequence data of other novel or nonculturable organisms in complex assemblages.

16 November 2006 in Journal of Phycology
Verified
Journal Article
Closed access
PDF file
MJMatthew D. Johnson
Matthew D. Johnson
TTTorstein Tengs
Torstein Tengs
DODavid Oldach
David Oldach
DSDiane K. Stoecker
Diane K. Stoecker